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Abstract
Background: The imperative to improve global health has prompted transnational research partnerships to
investigate common health issues on a larger scale. The Global Alliance for Chronic Diseases (GACD) is an alliance
of national research funding agencies. To enhance research funded by GACD members, this study aimed to
standardise data collection methods across the 15 GACD hypertension research teams and evaluate the uptake of
these standardised measurements. Furthermore we describe concerns and difficulties associated with the data
harmonisation process highlighted and debated during annual meetings of the GACD funded investigators.
With these concerns and issues in mind, a working group comprising representatives from the 15 studies iteratively
identified and proposed a set of common measures for inclusion in each of the teams’ data collection plans. One
year later all teams were asked which consensus measures had been implemented.
Results: Important issues were identified during the data harmonisation process relating to data ownership, sharing
methodologies and ethical concerns. Measures were assessed across eight domains; demographic; dietary; clinical
and anthropometric; medical history; hypertension knowledge; physical activity; behavioural (smoking and alcohol);
and biochemical domains. Identifying validated measures relevant across a variety of settings presented some
difficulties. The resulting GACD hypertension data dictionary comprises 67 consensus measures. Of the 14
responding teams, only two teams were including more than 50 consensus variables, five teams were including
between 25 and 50 consensus variables and four teams were including between 6 and 24 consensus variables, one
team did not provide details of the variables collected and two teams did not include any of the consensus
variables as the project had already commenced or the measures were not relevant to their study.
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Conclusions: Deriving consensus measures across diverse research projects and contexts was challenging. The
major barrier to their implementation was related to the time taken to develop and present these measures.
Inclusion of consensus measures into future funding announcements would facilitate researchers integrating these
measures within application protocols. We suggest that adoption of consensus measures developed here, across
the field of hypertension, would help advance the science in this area, allowing for more comparable data sets and
generalizable inferences.
Keywords: Implementation, Consensus Measures, Implementation Context, Hypertension, Low and middle income
countries
Background
The need to enhance global health research that can in-
form action on pressing health issues such as chronic
diseases, infectious diseases and maternal and child
health has prompted transnational partnerships among
researchers and research funders. These partnerships
can accelerate a critical mass of research directed at a
common health issue, foster new alliances and networks
among researchers that strengthen the overall research
endeavour and its likelihood for success, and provide a
common basis for decision making and advocacy using
the best available evidence. A critical enabler to achiev-
ing these aims is the development of common metrics to
maximize learning across multiple research projects.
There are two predominant models of global research
collaborations. The first model provides a means to an-
swer common research questions such as identification
of common risk factors and disease burden that require
large comparative multi-centre studies. Examples in-
clude collaborative projects such as the INTERHEART/
INTERSALT [1, 2], World Health Organization MON-
ICA project [3] and The Diabetes Attitudes, Wishes and
Needs (DAWN) study [4]. These research studies are
often undertaken in diverse settings. However, teams
typically share a common study design, measurement in-
struments and methodologies. In these initiatives, data
may be collected either contemporaneously or in se-
quence, but there is an underlying aim to facilitate ro-
bust comparisons by using pooled data to compare
effect sizes.
The second utilises partnerships to facilitate program
funding and policy development. Examples include the
Global Fund to Fight AIDS, Tuberculosis and Malaria [5];
GAVI, The Vaccine Alliance [6]; Global Alliance for the
Prevention of Obesity and Related Chronic Diseases [7],
and the Peers for Progress network [8]. These funding
programs tend to support research to determine the mag-
nitude of the problem, develop and implement interven-
tions and, in the case of low-and middle income countries
(LMICs), build research and workforce capacity. Projects
may be funded as a result of a request for applications
(RFA) specific to a research area or broad research
question. These RFAs tend to elicit projects with a diverse
set of interventions and methods and as such data vari-
ables and collection methods may not be consistent across
studies limiting the ability to perform cross site outcome
analysis and evaluation of implementation strategies.
Established in 2010, [9], the Global Alliance for
Chronic Diseases (GACD) [10, 11], is an example of a
transnational partnership of health research funding
agencies with aims and processes more similar to the
second model described above (see Table 1 for descrip-
tion of GACD- Organisational, funding and research
network processes). The broader aim of all funded re-
search through the GACD [10], is to lessen the burden
of multiple non-communicable diseases (NCDs) in
LMICs by developing interventions which are amenable
to scaling up and which incorporate disease specific out-
comes to assess efficacy [12]. Implementation science,
defined as “what works for whom and under what con-
textual circumstances, and is it scalable in equitable
ways?” [13] has been a basis for developing all of
GACD’s funding opportunities: This orientation provides
the basis for the GACD to achieve larger global impacts
as research teams examine how varying contexts (e.g.
health care financing, governance, health human re-
source capacity, accessibility of health care etc.) influ-
ence interventions and their scalability; and how existing
implementation gaps can be closed and health inequities
reduced.
The initial GACD funding round (see Table 1 for
GACD organisational, funding and research network
processes [10]), described here, focused on prevention,
management and control of hypertension and empha-
sised implementation science relevant and suitable to
LMIC settings, and in Aboriginal communities within
Canada and Australia (here after referred to as LMICs)
[11]. Fifteen projects across sixteen countries received
more than US$23 million committed over five years in
response to this first round of GACD Hypertension
RFAs (Fig. 1). National funding agencies announced suc-
cessful projects over a 6 to 9 month period during 2012,
(Fig. 2) which resulted in projects having different start-
ing dates.
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The GACD Board asked that a common set of clinical
outcomes be used to enable comparisons of outcomes
across funded projects. Thus, common text was included
in the Request for Applications (RFAs) from each agency
regarding expectations of research teams to share data,
to develop approaches to standardise data collection
and, wherever feasible, use these standardised ap-
proaches in their respective projects [11]. However, a
recent systematic review of interventions aimed at mul-
tiple risk factors for primary prevention of cardiovascu-
lar disease (CVD) in LMICs revealed only 13 eligible
studies. The authors found that the pooled estimates of
effect size for risk factor changes was questionable due
to heterogeneity of data [14], and there was no investiga-
tion of the role of contextual factors in explaining this
heterogeneity. In another review of lifestyle interventions
to lower blood pressure (BP) and assess the multiple
intervention effect on BP in LMIC, geographical or
country specific context heterogeneity was limited to
ethnicity [15]. Recently statistical modelling and data
pooling, such as that used by the NCD Risk Factor Col-
laboration to estimate global trends in blood pressure,
have informed the global epidemiology of blood pressure
[16]. However, several limitations to this approach, in-
cluding scarcity of primary data from LMICs and incon-
sistent protocols and measurement devices for collecting
primary data over time and between countries (digital vs
standard mercury sphygmomanometer), likely resulted
in wider uncertainties of estimates for some regions and
countries.
The aims of this paper are: a) to describe the experi-
ence of identifying, developing and encouraging the use
of a common set of standard indicators that would en-
able comparisons of clinical outcomes across the 15
funded hypertension projects and also enhance under-
standing of implementation strategies to prevent and
control hypertension in LMICs and b) to evaluate/exam-
ine the uptake and utility of recommendations for data
harmonization by funded hypertension research teams.
Methods
See Table 2 and Fig. 2 for timeline outlining the process
of data harmonisation, data dictionary development and
implementation evaluation.
Preliminary discussion of data harmonisation and sharing
Discussions concerning the potential for both data shar-
ing and data harmonisation and standardisation were
initiated at the 2012 GACD Joint Technical Steering
Committee (JTSC), (now known as the GACD Research
Network (GRN)), Annual Scientific Meeting (ASM) in
Ottawa (8–11 December 2012) (Table 2 and Fig. 2). This
took place 6 months after the announcement of the suc-
cessful hypertension projects. Representatives from all
hypertension research projects and funding agencies
were present. During this meeting a discussion group,
comprising representatives interested in data harmonisa-
tion from some of the 15 research teams, was formed to
discuss shared data opportunities, identify potential is-
sues relating to the logistics and value of data sharing
and to make recommendations to the JTSC Ottawa
meeting for further discussion of data harmonisation
Table 1 Global Alliance for Chronic Diseases (GACD) -
Organisational, funding and research network processes [10, 11]
The GACD member agencies are National public funding agencies that
primarily fund health research in their own countries. These agencies
have come together as a global alliance to contribute to and support
infrastructure and research programmes under the auspices of the
GACD through finance and management.
GACD alliance members agree on joint research priorities and fund
world-class research, fostering collaboration of research programmes be-
tween low-and middle income countries and high income countries to
fight chronic diseases. Alliance members issue joint requests for applica-
tions (RFAs) on a regular basis on topics in strategic focus areas.
Responses to RFAs undergo rigorous peer review through Alliance
member’s existing funding processes, although alliance members are
moving towards joint peer review by all member agencies. To date, this
model has been piloted on a small scale on two of the previous
funding calls, and rollout to all agencies is expected for 2017. While this
peer-review panel makes recommendations for funding, funding deci-
sions are ultimately made by each of the GACD member agencies, and
they are the bodies who award and administer all research funds.
The research teams that receive funding as part of a GACD research
programme form a community of researchers and funding agency
representatives under the banner of the GACD Research Network (GRN).
Through the network, members have the opportunity to participate in
joint activities in order to share information and develop common
approaches to their research. The Research Network meets annually at
the GACD Annual Scientific Meeting, with additional conference calls
throughout the year. The joint activities take the form of a number of
Working Groups, which are formed and chaired by researchers who
choose to work together on common themes across their projects. The
collaborative efforts of the GACD Research network and its Working
groups are supported by the GACD Secretariat, which is based in
London, UK.
Current member agencies of GACD (as of December 2016):
• Argentinian Ministry of Science and Technology (MINCYT), Argentina
• National Health and Medical Research Council (NHMRC), Australia
• São Paulo Research Foundation (FAPESP), Brazil
• Canadian Institutes of Health Research (CIHR), Canada
• Chinese Academy of Medical Sciences (CAMS), China
• Research & Innovation DG, European Commission, EU
• Indian Council of Medical Research (ICMR), India
• Agency for Medical Research and Development (AMED), Japan
• National Institute of Medical Sciences and Nutrition Salvador Zubirán,
Mexico - funding available through Conacyt
• South African Medical Research Council (SA MRC), South Africa
• Health Systems Research Institute, Thailand
• Medical Research Council (MRC), United Kingdom
• National Institutes of Health (NIH), United States
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and sharing opportunities, the logistics of data manage-
ment, value of data sharing to all teams and ethical
considerations.
A working group whose members were representatives
from 8 of the 15 research teams and of the GACD fund-
ing agencies was formally convened in early 2013 by
teleconference attendance.
Data sharing and harmonization process
As an initial step, the working group aimed to gain a
greater understanding of the protocols and proposed
measurements planned by each research team; to assess
commonalities, beyond their joint focus on hypertension;
and to use this information to establish standard vari-
ables and methodologies for a number of measures. This
dataset would then serve as a framework for potential
future cross-site analyses, and also as a reference source
for research teams who were yet to establish their data
collection methods.
Following this initial scoping survey of the 15 teams,
working group members summarised data for eight do-
mains comprising demographic, dietary, clinical and
anthropometric, medical history, hypertension know-
ledge, physical activity, behavioural (smoking and alco-
hol), and biochemical domains; and then identified any
existing concordance in measurement methods. Based
on this initial analysis the working group prepared, and
iteratively refined, a set of standardised variables using
a modified (non-anonymous) Delphi technique [17].
This summary exercise was completed in August 2013
(Table 2 and Fig. 2).
At the 2013 GACD ASM, over a year after the initial
JTSC (GRN) meeting (Table 2 and Fig. 2), the working
group presented its recommendations for the common
measures to be adopted in the form of the data diction-
ary (Additional file 1: Table S1). After further refine-
ments based on feedback received at the meeting, the
final version of the data dictionary was released to the
research teams in February, 2014 (Table 2 and Fig. 2).
A follow-up survey was circulated in February 2015
(Table 2 and Fig. 2) to the 15 funded research teams
asking whether or not they had included any of the
consensus measures in their data collection, which
measures they had included, and their reasons for in-
cluding (already part of their planned protocol, to
allow comparison with other groups, consensus mea-
sures were superior to planned measures) or not in-
cluding (data collection imminent, not relevant to
population/study, didn’t see value in comparing with
other groups, IRB/permit constraints, financial/logis-
tical constraints, unaware of consensus data diction-
ary) the consensus measures.
Results
When opportunities and recommendations of the dis-
cussion group were initially shared with the JTSC
(GRN), comprising all hypertension teams, at the 2012
Ottawa ASM doubts were raised about the value of
Fig. 1 GACD Hypertension funding agencies and location of each data collection site. Countries/Regions in blue indicate original GACD funding
partners for the GACD Hypertension (HT) programme. Countries in orange indicate low-middle income (LMIC) partner countries for HT research.
Circles indicate LMIC location of research project
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joint data analysis, given that not all of the studies in-
cluded population based data collection, and the inter-
ventions were diverse. Other concerns expressed were
over (1) data ownership; (2) data sharing methodology;
(3) the addition of variables not previously included in
original protocols and potentially extraneous to the ori-
ginal study aims; and (4) ethical issues such as collect-
ing data not directly related to the research question or
adding protocols after the ethics approval process had
been initiated. The ethical aspects of collecting data
that would be shared with other researchers were vigor-
ously debated and discussed. Researchers suggested
that such activity would need to be included in partici-
pant information and consent forms. Some researchers
believed that their study populations may have diffi-
culty in understanding the concept of data sharing
among teams and such activities may be a barrier to
successful recruitment and furthermore create suspi-
cion among study participants about what would hap-
pen to their data and how it would be used. Despite the
aforementioned concerns which we discuss further in
this article, the consensus of the representatives
attending the 2012 ASM was to form a working group
to progress data harmonisation among the 15 research
teams.
The initial scoping exercise, by the formal working
group during March – August, 2013 (see Table 2 and
Fig. 2) yielded mixed results. Although there appeared
to be large potential for data standardisation, there
were discrepancies in both the types of variables col-
lected and the methods and protocols to measure
common variables (such as blood pressure (BP)).
There was considerable variation in the degree of
overlap in measures among research groups, but the
greatest consistency was observed in planned mea-
surements relating to BP, current smoking status, an-
thropometry, physical activity and medical history
(previous diagnosis of diabetes/hypertension/stroke or
hypertension medication).
Differences in methodologies were associated with the
planned intervention, the study setting (health care/clin-
ical setting vs community based), the target population
(e.g. school children, adults, policy-makers), cross cultural
considerations (particularly in the domains of nutrition
and tobacco use) as well as relevance of the measures to
the main research question (s) of each research team.
Particular difficulties were experienced in (1) identify-
ing validated measures (e.g. diet and physical activity),
Fig. 2 Data harmonisation process and evaluation timeline
Table 2 Timeline of data harmonisation, data dictionary
development and evaluation
Date of activity Activity undertaken
March–August, 2012 Successful Hypertension GACD Programme
awardees announced.
December,2012–
February, 2013
Discussion group formed at GACD ASM.
Data Standardisation Working Group proposed
and agreed upon.
March, 2013 Data Standardisation Working Group formally
constituted.
March–August, 2013 Scoping exercise to identify potential consensus
variables and summarise data across eight
domains for all Hypertension Programme
projects.
August–November,
2013
Data dictionary drafted as a recommended set
of consensus measures based on previous
scoping exercise and summary steps
November, 2013 Data Standardisation Working group presents
recommendations for common measures to be
adopted at 2013 GACD ASM.
December, 2013–
February, 2014
Further refinement of draft data dictionary
based on feedback received at 2013 GACD ASM.
February, 2014 Final version of consensus data dictionary
released
February, 2015 Follow-up survey conducted to assess level of
adoption of recommended measures.
April–November,
2015
Analysis of implementation of data dictionary by
teams
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which were relevant across diverse ethno-cultural set-
tings and pertinent for populations from varying socio-
economic positions; and (2) balancing the use of well
validated measures with what was logistically possible
and pertinent for studies that were being undertaken in
health care settings ranging from rural and remote pri-
mary care clinics to tertiary care hospitals. Teams also
believed that the addition of unplanned variables would
likely increase participant burden and possibly affect re-
cruitment and participation. There were also teams with
interventions that focused on policy rather than behav-
ioural outcomes changes. These teams were concerned
about the pertinence of clinical measures for their
studies.
Despite these concerns, the GACD hypertension data
dictionary was developed (Additional file 1: Table S1)
based on the initial scoping survey of the 15 funded
teams and the iterative process undertaken by the work-
ing group to summarise and identify appropriate mea-
sures for inclusion in the data dictionary. It comprised a
total of 67 consensus measures across eight common
domains (Table 3 and Additional file 1: Table S1): demo-
graphic; dietary; clinical and anthropometric; medical
history; hypertension knowledge; physical activity; be-
havioural (smoking and alcohol), and biochemical.
One team did not respond to the follow up survey in
February 2015. Of the 14 responding teams, only two
teams were including more than 50 consensus variables,
five teams were including between 25 and 50 consensus
variables and four teams were including between 6 and
24 consensus variables. One team did not provide details
of the variables being collected and two of the 14 teams
indicated that they did adopt any of the standardised
methods. Additional file 1: Table S1 details the number
of teams collecting each of the consensus measures.
Measurements relating to the demographic domain (date
of birth, highest education, sex), clinical/anthropometry
domain (blood pressure, pulse rate, anthropometry), be-
havioural (smoking) domain (current smoking status),
physical activity domain (physically active for more than
30 min five times/week, how much time spent walking
or cycling) and medical history (previous diagnosis of
diabetes/hypertension/stroke or hypertension medica-
tion) were being collected by eight or more of the 11
teams (Additional file 1: Table S1). Of the two teams not
including any of the measures, one had already submit-
ted applications for ethics approval and data collection
was imminent by the time the consensus variables were
available and the other team, assessing cost effectiveness
of salt reduction intervention in the Pacific Islands, de-
termined the standardised measures were not relevant
for their study.
All eleven teams who included consensus variables in
their protocols, stated that the consensus variables they
were using were already included in their original proto-
cols, two of the teams indicated that they changed some
of their original data variables to align with the consen-
sus measures, stating the consensus measures were su-
perior to those initially planned. Five teams expressed
support for the consensus measures to enable data com-
parability with other teams.
Dietary measures proved particularly difficult to stand-
ardise given global dietary diversity (e.g. patterns of fruit,
vegetable and protein intake) and this was reflected in
the number of teams using the proposed dietary consen-
sus measures. Six teams planned to ask if salt was added
to meals during cooking and five teams planned to ask
about adding salt to food after cooking. Four teams
planned to ask about fruit, vegetable and protein con-
sumption and only three teams planned to ask about
dairy intake.
Discussion
The GACD Hypertension programme consists of 15
teams investigating a multitude of interventions with the
overall aim of improving the detection, treatment, and
monitoring of people with hypertension in resource-
limited settings. This study identified and described the
processes undertaken to harmonise the data collection
of the 15 research teams funded under the GACD
hypertension programme. Furthermore we highlight is-
sues and difficulties related to this harmonisation
process across the 15 teams.
Each team is contributing to the evidence-base within
its own particular context. However, the collaboration of
GACD teams would enhance this by enabling analyses
of baseline prevalence of hypertension and associated
risk factors across settings, enabling the broader
Table 3 Data domains within data dictionary
Domain Description
Demographic Participant age, gender and information relating to
household size and income.
Diet Variables collecting information on salt intake, and
meat/vegetable consumption.
Clinical/
Anthropometry
WHO STEPS [30] blood pressure protocol, and basic
anthropometric measurements.
Personal Medical
History
Participant’s history of CVD and diabetes.
Knowledge of
HTN
Participant’s knowledge and awareness of
hypertension.
Physical activity Details concerning patient’s level of regular physical
exercise.
Behavioural
Smoking Level of tobacco use
Alcohol Level of alcohol consumption.
Biochemical 24 h Urine and blood glucose measurement from
WHO STEPS biochemical core [30].
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evaluation of intervention modalities and implementa-
tion issues, and ensuring that setting and context are
considered when assessing individual and population
outcomes. The approach taken in the development of
the consensus measures was initially driven by clinical
outcome measures and known risk factors commonly
used in systematic reviews and meta-analysis. Whilst this
approach was appropriate for reporting baseline preva-
lence, analysis of implementation impact also requires
the inclusion of contextual variables, such as barriers
and facilitators, which may impact the intervention out-
comes and affect scalability. The development of con-
textual measures for implementation science is still a
nascent area of development [18].
Why develop consensus measures?
As can be seen from the GBD study [19] and studies
such as the DAWN study [4], consensus measures, col-
lected using consistent methodologies, can improve
overall estimates of impact. Taking the lead from other
areas of study (e.g. infectious disease, injury prevention,
and cancer control), the importance of a “case defin-
ition” is crucial for consistent identification of people
with hypertension and enhances comparability across
studies. Thus consensus measures can be particularly
valuable when comparing interventions, implementation
methods and individual and population outcomes across
different settings and contexts.
By sharing data that includes common outcome mea-
sures, research teams could potentially generate new hy-
potheses, be able to answer additional research
questions to their original project focus, and conduct
analyses with enhanced sample sizes and power. It could
also foster new collaborations and maximise use of each
project’s data. An example of such a collaboration be-
tween members of the GACD hypertension programme
identified, using the behaviour change wheel framework
[20], the ability to achieve behaviour change across re-
gions and between those responsible for health care de-
livery (clinicians, non-physician health workers and
policy makers) differed greatly [21]. The process of data
standardisation has also led to an increased understand-
ing of what data are necessary to answer the research
questions of the GACD programme as a whole, and the
opportunity for each research team to critically evaluate
their planned methodologies.
Weighing up accuracy and precision against feasibility of
consensus measures
In order to compare the impact of implementation strat-
egies across settings, we would typically propose the
consistent measurement of outcomes across sites. The
variety of methods to measure hypertension (e.g. auto-
mated BP vs manual sphygmomanometer) as well as
variability in clinical definitions of hypertension [22] ex-
acerbates difficulties in ensuring data consistency. While
there were consensus measures available, teams were
faced with pragmatic issues such as the need to measure
blood pressure using locally available equipment in dis-
trict health centres. This approach was in keeping with
the implementation science focus, with teams aiming to
examine the scale up of interventions under local condi-
tions. This orientation required that teams strike a bal-
ance between using clinical measures that are consistent
with usual care practices (and available equipment) ver-
sus using more refined measures (and newly acquired
equipment). While the latter provides better measure-
ment precision, it also introduces an intervention intru-
sion that may limit the accurate assessment of
intervention scalability.
Challenges to developing/implementing consensus
measures
Consistency of methods
Consensus measures should not only collect the same
information but also, where practical, collect it using the
same methodologies. In the case of blood pressure, vari-
ous methodologies exist from manual to automatic
readers, from one reading to three readings, ambulatory
or office bound. Thus consistency across various cultural
and geographical settings needs to be balanced between
the desire for scientific precision and real world
implementation.
Ethical issues
In discussions of lessons learned, the ethical aspects of
sharing data were identified. Data sharing intentions
should be clearly stated in any information shared with
the participants of the study and consent is necessary for
data sharing to occur. Therefore, consensus measures
and an understanding of the extent of data sharing
should be in place prior to ethical approval being sought
for the individual projects.
Further to this, ethics committees often discuss the
question of study relevance. Is it necessary and ethical to
collect data which will not specifically contribute to the
research question asked by the researchers? However, if
through data sharing, greater value is extracted from an
individual research project (and therefore from a partici-
pant’s involvement), there may exist an ethical impera-
tive for this sharing of data. This should be made
explicit at the outset through the inclusion of overarch-
ing questions that may be addressed via protocols using
shared data.
The ethical question of “who owns the data” is one
which should be negotiated and agreed upon by re-
searchers, participants and global collaborative teams
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prior to any data collection and might be aligned with
discussions of benefit and reciprocity.
The question of lack of reciprocity has been
highlighted by van Panhuis et al. [23] as an ethical issue
of data sharing for research involving LMICs. Benefits to
populations as well as researchers, who contribute data
to a collective analytic endeavour, must be clearly out-
lined and established at the outset. Such benefits might
include health improvements for participating communi-
ties, and more equitable scientific outputs by participat-
ing researchers.
Benefits of collecting consensus measures
Developing and collecting consensus measures can con-
tribute better quality data to hasten global research ef-
forts targeting prevention and management strategies
for NCDs and their scale-up. Furthermore, developing
global collaborations in which researchers operate inde-
pendently and yet contribute cooperatively to inform the
same research area can potentially minimise redundan-
cies in data collection and implementation strategies.
Consensus measures collected consistently from differ-
ent settings provide invaluable information for imple-
mentation strategies. Intervention outcomes to evaluate
intervention effectiveness (“relative advantage”) [24] as
well as information about context, setting and individual
characteristics have been highlighted as important com-
ponents of proposed frameworks to enhance implemen-
tation, such as the Consolidated Framework for
Implementation Research [25]. The experience of the
hypertension teams suggest that a larger set of compara-
tive processes and outcomes can be examined than those
traditionally examined in meta-analyses [21].
In addition, publication of these consensus measures
may encourage new research teams that are not part of
the GACD, to adopt these measures enabling them to
contribute to the collective research effort on chronic
disease prevention and management.
Identifying gatekeepers and managers of consensus data
Collecting data and developing protocols and data for-
mats for shared data can be complicated and time con-
suming. Few recipients of funds will have budgeted for
this activity, if they have not been prompted to do so.
Funding partners may need to develop data sharing pol-
icies and formal data sharing mechanisms to enable re-
searchers to include such activities in their applications.
The decision about who will be the gatekeepers of
shared data; who will have access to the data and on
what basis, need to be well established early to avoid po-
tential conflicts or disagreements about the use of such
data. This agreement should be obtained by members of
the contributing research teams and authorship of any
subsequent publications should have a clearly outlined
policy and framework for all team members to follow.
Issues of data access and ownership by Indigenous com-
munities, such as those specified in the principles of
ownership, control, access and possession [26, 27], also
need to be taken into consideration.
Who should guide the development of consensus
measures and when should they be announced?
One option to ensure early adoption of consensus mea-
sures is for individual funding agencies to mandate what
data and what related measurement methodologies
should be used. However, this approach risks stifling in-
novative and novel research approaches, restricting in-
vestigation into the “known unknowns” or burdening
research teams with the requirement to collect measures
that may be irrelevant to their original research question.
Alternatively, consensus measures could be developed as
soon as funded projects are announced, with experts in
the field recommending appropriate consensus measures
(based on those already being proposed). This would en-
able teams to continue to pursue their original research
hypothesis as well as contribute data to the greater col-
laboration. Importantly, this approach would potentially
enable consistency of methodologies and definitions to
be incorporated into protocols before submission to eth-
ics review boards. With respect to the GACD, a number
of the consensus measures developed for hypertension
have applicability to other chronic diseases and we are
encouraging the adoption of these measures by teams
recently funded to address type 2 diabetes.
In addition to health-related outcomes, specifying re-
quirements for some “higher-order” data about cultural,
economic, policy and health system contexts to be col-
lected would allow better learning about approaches to
hypertension control that do or do not work across di-
verse contexts [13, 18, 28]. Shared learnings between
groups under this funding arrangement can be realised
through collaboration and networking between group
members [21]. Such insights are an important goal for
the implementation science agenda of the GACD
programme overall.
Health research funding agency protocols and timelines
The degree to which the GACD Hypertension
Programme research teams adopted the set of consensus
measures was influenced by several features of the
GACD collaboration. Despite all GACD funding agen-
cies including language on data sharing in their RFAs,
clear direction and guidance on the likely additional out-
comes of interest (beyond hypertension) were not avail-
able to teams when developing their research proposals.
Successful projects were not announced by all funding
agencies concurrently and funds were released to all suc-
cessful research teams over a 6 to 9 month window.
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Therefore the first meeting of the JTSC (GRN) and the
establishment of a core measure consensus group took
place after some teams were well advanced with devel-
oping measurement tools, and submitting ethics applica-
tions. The consensus data dictionary was developed as
an outcome of the first meeting of the JTSC (GRN) but
the delay (~18 months) in the release of the data dic-
tionary, meant that most teams were already commen-
cing data collection when the data dictionary was
provided. Ultimately only two of the fifteen GACD
teams amended their study protocol to accommodate
any consensus measures. However, a further 9 teams in-
dicated that some of the consensus measures were
already incorporated in their initial protocols.
This underscores the importance that data standard-
isation and data sharing issues be tackled early by con-
sortia and that all funding partners and potential
researchers should develop a common vision of future
joint analysis activities from the outset.
Conclusion
This paper has described the process of conceptualising
and developing a set of consensus measures that would
allow robust, relevant, and reliable comparisons to be
made across projects and has outlined some of the chal-
lenges and questions to guide development of consensus
measures in other global studies. Whilst standardising
data collection methods and sharing the resultant data-
sets is an attractive proposition for both researchers and
funding agencies alike, establishing a set of consensus
measures requires a significant investment in effort from
all parties, and substantial preparatory work. Implemen-
tation science will yield deeper insights more quickly if
consensus measures are established for both health out-
comes and contextual parameters. Relevant and work-
able data standardisation and sharing policies must be put
in place to yield the potential benefits of collective efforts
to analyse cross-project data. Policy trends towards in-
creased open access to clinical trial data [29], make these
consensus efforts timely and more achievable.
Key recommendations:
➢ Researchers and funders need to share a common
vision for joint programme activities
➢ Clear and specific language on data standardisation
and sharing should be included in the RFA.
➢ Funded teams should be brought together as soon as
possible after funding announcements making use of
communication technology to facilitate group contact.
➢ Consensus measures (both the outcome and context
variables and the measurement approach) need to be
developed as early as possible, preferably prior to ethics
approval and participant recruitment.
➢ Adopt a pragmatic approach to balancing precision
and direct comparability of common measures with the
aims of implementation science including scalability.
➢ Measures of intervention context should be included
in the consensus measures.
➢ Data sharing intentions should be included in
informed consent documents.
➢ Make the consensus measures easily accessible so
that others can utilise similar methods and approaches,
and contribute to a data repository.
Additional file
Additional file 1: Table S1. GACD hypertension consensus variables,
suggested collection methods and number of teams using
variable.(DOCX 36 kb)
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